### ANNUAL BURDEN ESTIMATES

<table>
<thead>
<tr>
<th>Instrument</th>
<th>Annual number of respondents</th>
<th>Number of responses per respondent</th>
<th>Average burden hours per response</th>
<th>Total annual burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discussion Guide for Use with Tribal TANF administrators</td>
<td>13</td>
<td>1</td>
<td>2</td>
<td>26</td>
</tr>
<tr>
<td>Discussion Guide for Use with Tribal TANF staff</td>
<td>12</td>
<td>1</td>
<td>1</td>
<td>12</td>
</tr>
<tr>
<td>Discussion Guide for Focus Groups with Tribal TANF clients</td>
<td>20</td>
<td>1</td>
<td>2</td>
<td>40</td>
</tr>
<tr>
<td>Discussion Guide for Use with staff of related programs</td>
<td>20</td>
<td>1</td>
<td>1</td>
<td>20</td>
</tr>
<tr>
<td>All Instruments</td>
<td>65</td>
<td></td>
<td></td>
<td>98</td>
</tr>
</tbody>
</table>

**Estimated Total Annual Burden Hours:** 98.

In compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Planning, Research and Evaluation, 370 L’Enfant Promenade, SW., Washington, DC 20447, Attn: OPRE Reports Clearance Officer. Email address: OPREinfocollection@acf.hhs.gov. All requests should be identified by the title of the information collection.

The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: October 26, 2011.

Steven M. Hamner,
Reports Clearance, Officer.
[FR Doc. 2011–28292 Filed 11–1–11; 8:45 am]
BILLING CODE 4184–09–M

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Administration for Children and Families**

**President’s Committee for People With Intellectual Disabilities Meeting, Via Conference Call, Cancellation**

**AGENCY:** President’s Committee for People with Intellectual Disabilities (PCPID).

**ACTION:** Notice of PCPID Conference Call Cancellation.

**DATES:** The conference call was scheduled for October 28, 2011, 1 p.m. to 2:30 p.m.

**FOR FURTHER INFORMATION CONTACT:** Laverdia Taylor Roach, Senior Advisor, President’s Committee for People with Intellectual Disabilities, The Aerospace Center, Second Floor West, 370 L’Enfant Promenade SW., Washington, DC 20447. Telephone: (202) 619–0634. Fax: (202) 205–9519. Email: LRoach@acf.hhs.gov. Further meetings will be announced through a separate Federal Register notice.

Dated: October 26, 2011.

Jamie Kendall,
Deputy Commissioner, Administration on Developmental Disabilities.

[FR Doc. 2011–28292 Filed 11–1–11; 8:45 am]
BILLING CODE 4184–01–P

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. FDA–1999–D–2955]

**Revised Guidance for Industry on Impurities: Residual Solvents in New Veterinary Medicinal Products, Active Substances and Excipients (Revision), VICH GL18(R); Availability**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of a revised guidance for industry (#100) entitled “Impurities: Residual Solvents in New Veterinary Medicinal Products, Active Substances and Excipients (Revision)” VICH GL18(R). This revised guidance has been developed for veterinary use by the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH). The guidance is intended to recommend acceptable amounts of residual solvents in new animal drugs (referred to as pharmaceuticals or veterinary medicinal products in this guidance) for the safety of the target animal as well as for the safety of human consumers of products derived from treated food producing animals. It is intended to assist in developing new animal drug applications (referred to as marketing applications in this guidance) submitted to the European Union, Japan, and the United States.

**DATES:** Submit either electronic or written comments on Agency guidances at any time.

**ADDRESSES:** Submit written requests for single copies of the guidance to the Communications Staff (HFV–12), Center for Veterinary Medicine, Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855. Send one self-addressed adhesive label to assist that office in processing your requests. See the SUPPLEMENTARY INFORMATION section for electronic access to the guidance document.

Submit electronic comments on the guidance to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

**FOR FURTHER INFORMATION CONTACT:** Mai Huynh, Center for Veterinary Medicine (HFV–142), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, (240) 276–8273, mai.huynh@fda.hhs.gov.

**SUPPLEMENTARY INFORMATION:**